BNT162b2疫苗接种者过敏风险评估算法的效果
在6146名医院员工中,通过筛查问卷识别出118名有严重过敏背景者并分为低、中、高危三组,评估BNT162b2疫苗过敏反应。过敏人群中14%出现超敏反应,高危组发生率35%高于中危组10%(p=0.005)。
要点
- 严重过敏背景者接种BNT162b2后超敏反应发生率为14%,皮肤表现最常见。
- 高危组超敏反应发生率35%,显著高于中危组10%(p=0.005)。
核心结论
- BNT162b2 mRNA新冠疫苗对有严重过敏背景者相对安全,但高危患者需采取预防措施。
研究设计与样本
- 对6146名医院员工进行筛查问卷,识别出118名有严重过敏背景者,根据过敏病史分为低危、中危和高危三组,收集过敏和非过敏受试者的超敏反应数据。
主要发现
- 高危组过敏事件发生率35%,中危组10%(p=0.005),低危组0%(p=0.074)。
- 无患者发生过敏反应(anaphylaxis),所有患者完成接种程序。
临床怎么用
- 对有严重过敏背景者接种BNT162b2前应进行风险评估,高危患者需采取预防措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Among 6146 hospital employees, 118 subjects with severe allergic background were identified through a screening questionnaire and stratified into 3 groups (Low-risk (LR), Intermediate (IR) and High-risk (HR) group), based on their allergic anamnesis. Data reports on hypersensitivity reactions (HypR) have been collected in both allergic and non-allergic subjects. Seventeen patients (14%) in the allergic population had a HypR after the first, the second or both doses. Skin manifestations were the most frequent ones. Allergic events were more frequent in HR (35%) than IR (10%; p = 0.005) or LR (0%; p = 0.074) subjects. No patient had anaphylaxis. All patients completed the vaccination schedule. 13 HypR occurred in patients without severe allergic background (13/6028, 0,2%) including one (1/6148, 0.016% of total population) WAO grade-4 anaphylaxis. Our data suggest that BNT162b2 mRNA Covid-19 vaccine is relatively safe also in patients with severe allergic background; however, some precautions are required for high-risk patients.
引用
- Yacoub MR, Cucca V, Asperti C, et al. Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine. Vaccine. 2021. PMID: 34598820. doi:10.1016/j.vaccine.2021.09.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。